CRTd Responders Optimization
Optimization of Cardiac Resynchronization Therapy and Its Effects in Patients With Type 2 Diabetes Mellitus: Automatic Optimization vs. Echocardiographic Guided Optimization.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Napoli, Italy
- Celestino Sardu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- heart failure with reduced cardiac pump, NYHA class II/III, indication to receive a CRTd.
Exclusion Criteria:
- NYHA class IV, previous CRTD implantation, neoplastic disease, inflammatory chronic disease.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
T2DM patients with CRTd with automatic optimization
In this cohort the T2DM patients with CRTd will receive at follow-up an automatic optimization of CRTd.
|
|
|
T2DM patients with CRTd with echocardiographic optimization
In this cohort the T2DM patients with CRTd will receive at follow-up an echocardiography guided optimization of CRTd.
|
the patients after the implant of CRTd and during the follow-up will receive an echocardiography to optimize the atrio-ventricular and inter-ventricular delay, and to improve the effects of CRTd.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CRTd responders rate
Time Frame: 12 months
|
The authors will evaluate the CRTd responders rate in terms of patients that will experience the reduction of NYHA class, improvement of HF symptoms, and improvement of left ventricle ejection fraction.
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 08.09.20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
NCT07199088RecruitingAcute Decompensated Heart Failure | Heart Failure, Diastolic | Heart Failure, Systolic
-
NCT07356843RecruitingCongestive Heart Failure | Congestive Heart Failure (CHF) | Congestive Heart Failure Chronic | Congestive Heart Failure(CHF)
-
NCT03157219UnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart Failure
-
NCT02084992CompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart Failure
-
NCT03387813CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive
-
NCT07263035RecruitingHeart Failure | Heart Failure Acute | Acute Heart Failure (AHF) | Heart Failure - NYHA II - IV
-
NCT04281849CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure Acute
-
NCT07547540Not yet recruitingHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic
-
NCT00123955CompletedHeart Failure, Congestive | Diastolic Heart Failure
-
NCT01411735CompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
Clinical Trials on echocardiographic optimization of CRTd
-
NCT02008305TerminatedOcclusion or Malformation of a Cerebral Vessel
-
NCT07209956Completed
-
NCT05964569Recruiting
-
NCT02740764UnknownFunctional Autonomy Level
-
NCT05936294TerminatedRight Bundle-Branch Block
-
NCT01925105Unknown
-
NCT05573997RecruitingCardiovascular Diseases | Heart Failure | Valvular Heart Disease | Biochemical Dysfunction
-
NCT01877499CompletedRenal Replacement Therapy | End-stage Renal Disease | Hemodiafiltration | Convection Volume
-
NCT05998278RecruitingProstate Adenocarcinoma